A recent study investigating the role of dietary supplements in cognitive health found that while high doses of DHA successfully elevated participants’ DHA levels, this increase did not correlate with any measurable improvement in cognitive function. The findings suggest that the supplementation of DHA may not be effective in preventing cognitive decline associated with dementia. The research was motivated by existing knowledge linking certain genetic markers and lipid levels to neurodegenerative conditions.
Specifically, individuals carrying the APOE ε4 allele gene are known to have an elevated risk of developing Alzheimer’s disease. Furthermore, lower levels of DHA have been previously associated with the progression of this type of disease. To test this hypothesis, researchers conducted a study involving participants aged 55 to 80 years old.
Crucially, all participants were free from a diagnosis of dementia at the outset and reported low baseline intake of DHA, alongside possessing at least one identified risk factor for either dementia or cardiovascular diseases. The objective was to determine if administering high doses of DHA could mitigate the risk associated with the disease. Despite the successful supplementation and resulting increase in measured DHA levels within the study group, the investigators reported no corresponding benefits to the participants’ cognitive performance.
This outcome leads researchers to reconsider the prophylactic role of supplemental DHA in managing the risk factors associated with Alzheimer’s disease, suggesting that current supplementation strategies may not be sufficient to alter the course of the disease.
Topics: #dha #alzheimer #disease
